Watson Pharmaceuticals Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Watson Pharmaceuticals's estimated annual revenue is currently $126.4M per year.(i)
  • Watson Pharmaceuticals's estimated revenue per employee is $251,851

Employee Data

  • Watson Pharmaceuticals has 502 Employees.(i)
  • Watson Pharmaceuticals grew their employee count by -3% last year.

Watson Pharmaceuticals's People

NameTitleEmail/Phone
1
Senior ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$46.2M22116%N/AN/A
#2
$43.8M21821%N/AN/A
#3
$57.1M28426%N/AN/A
#4
$24.5M91-10%N/AN/A
#5
$52.9M26313%N/AN/A
#6
$24.7M12313%N/AN/A
#7
$1.8M16-6%$114.3MN/A
#8
$7.2M28-7%N/AN/A
#9
$13.7M51-9%N/AN/A
#10
$7.6M39-13%$123.9MN/A
Add Company

What Is Watson Pharmaceuticals?

Watson Pharmaceuticals, Inc. (NYSE-WPI) is a global specialty pharmaceutical company with approximately $3 billion in revenues, a broad product line and operations in well-established and emerging markets.

keywords:N/A

N/A

Total Funding

502

Number of Employees

$126.4M

Revenue (est)

-3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Watson Pharmaceuticals News

2022-04-19 - Parties feel time crunch in opioid trial as testimony shows opioid ...

Attorneys representing the defendants — Teva Pharmaceutical Industries LLC and a ... Leitch discussed Watson's purchase of the drug Kadian,...

2022-04-17 - Attorney general announces $99 million settlement with Janssen ...

The Allergan defendants include Allergan Finance, LLC, formerly known as Actavis, Inc., fka Watson Pharmaceuticals, Inc.; Allergan Sales LLC...

2022-04-17 - West Virginia AG Morrisey announces $99M settlement with Janssen Pharmaceuticals

The Attorney General alleged Janssen Pharmaceuticals Inc., ... LLC; Actavis Pharma Inc., fka Watson Pharma Inc.; Actavis South Atlantic LLC;...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$169.4M5029%N/A
#2
$64M5026%N/A
#3
$104.5M50227%N/A
#4
$157.5M5020%N/A
#5
$156.9M502-47%N/A